John McKay Joins biOasis Technologies Inc.'s Advisory Board

biOasis Technologies Inc. (the "Company") (TSX VENTURE:BTI) is pleased to
announce the appointment of Mr. John McKay as a member of the Company's Advisory
Board. "John has vast expertise in the Pharmaceutical and Biotech fields," says
Rob Hutchison, CEO, "his industry knowledge and contacts gained through 20 years
with SmithKline Beecham, 10 years with Warner Lambert / Parker David, and
through his consultancy work are extremely valuable to biOasis."


Since late 2000, John established JHM PharmaServices to provide consultancy
services in Marketing Strategy, Business Development, Product Assessment and
Licensing to various large Pharmaceutical and Bio-Pharmaceutical clients.


Prior to that John was 20 years with SmithKline Beecham, most latterly as Vice
President and Director Global Marketing (formerly Strategic Product
Development). In this role he was responsible for the worldwide commercial
development of major products and the new product pipeline.


During his career he has held General Management and Marketing Management
positions in Canada, Brazil, Italy, Latin America and China for SmithKline
Beecham and for Warner Lambert. Prior to entering the pharmaceutical industry he
had experience in science and new product development positions in the animal
agriculture industry.


He holds Science and Business degrees from Mount Allison University and Queens
University in Canada.


About the Company

biOasis Technologies Inc. is a Canadian Biotechnology company engaged in the
development and commercialization of diagnostics and therapeutics related to
neurological diseases. It has extensive and comprehensive intellectual property
("IP") which it obtained from the University of British Columbia. The Company's
initial area of focus will be on the utilization of the IP to pursue a biomarker
for the diagnosis of Alzheimer's disease. The IP has been corroborated in double
blinded and successive multi-site clinical trials.


According to the Centers for Disease Control and Prevention ("CDC"), Alzheimer's
disease was listed as the "underlying cause of death" for 65,829 Americans in
2004. It was the seventh leading cause of death for people of all ages and the
fifth leading cause of death in people age 65 and older.


To find out more about biOasis Technologies Inc. visit www.bioasis.ca.

On Behalf of the Board of Directors

Robin Hutchison, Director and CEO